

Percentage of Public Drug Program Spending on Generic Drugs

Name	Percentage of Public Drug Program Spending on Generic Drugs
Short/Other Names	Not applicable
Description	The rate of public drug program spending on generic drugs
Interpretation	This indicator is interpreted as the proportion of public drug program spending for generic drug products.
HSP Framework Dimension	Health System Inputs and Characteristics: Efficient allocation of resources
Areas of Need	Not applicable
Geographic Coverage	Newfoundland and Labrador, Prince Edward Island, New Brunswick, Nova Scotia, Quebec, Ontario, Manitoba, Saskatchewan, Alberta, British Columbia, Yukon
Reporting Level/Disaggregation	Province/Territory
Indicator Results	https://secure.cihi.ca/estore/productSeries.htm?locale=en&pc=PCC1011

Identifying Information

Name Percentage of Public Drug Program Spending on Generic Drugs

Short/Other Names Not applicable

Indicator Description and Calculation

Description The rate of public drug program spending on generic drugs

Total public drug program spending on generic drugs divided by total public drug program spending

Calculation: Description

Unit of Analysis: Spending from public drug programs

Calculation: Geographic Assignment

Place of residence

Calculation: Type of Measurement

Percentage or proportion

Calculation: Adjustment Applied

None

Calculation: Method of Adjustment

Not applicable

Description:

Total public drug program spending

Inclusions:

Denominator All claims accepted by public drug programs

Exclusions:

Any claims not submitted to or accepted by public drug programs, including claims submitted to a private insurer or cases where the individual pays out of pocket

Description:

Total public drug program spending on generic drug products

Inclusions:

Numerator All claims for generic drugs accepted by public drug programs

Exclusions:

1. Any claims not submitted to or accepted by public drug programs, including claims submitted to a private insurer or cases where the individual pays out of pocket

2. Claims for brand name products

Background, Interpretation and Benchmarks

Rationale This indicator measures the proportion of public drug program spending that generic drugs account for.

Interpretation This indicator is interpreted as the proportion of public drug program spending for generic drug products.

HSP Framework Dimension Health System Inputs and Characteristics: Efficient allocation of resources

Areas of Need Not applicable

Targets/Benchmarks Not applicable

References Not applicable

Availability of Data Sources and Results

Data Sources NPDUIS Database

Type of Year:

Calendar

First Available Year:

Available Data Years

	2000
	Last Available Year:
	2017
Geographic Coverage	Newfoundland and Labrador, Prince Edward Island, New Brunswick, Nova Scotia, Quebec, Ontario, Manitoba, Saskatchewan, Alberta, British Columbia, Yukon
Reporting Level/Disaggregation	Province/Territory
Result Updates	
Update Frequency	Whenever required for analytical product or data request
	Web Tool:
Indicator Results	<i>Prescribed Drug Spending in Canada</i>
	URL: https://secure.cihi.ca/estore/productSeries.htm?locale=en&pc=PCC1011
Updates	Not applicable
Quality Statement	
Caveats and Limitations	<ul style="list-style-type: none"> – Includes only drugs claimed through public drug programs – Excludes any drugs claimed through a private drug plan or purchased over the counter <p>All data is not available for all years:</p> <ul style="list-style-type: none"> – Manitoba, Saskatchewan, Alberta, New Brunswick: From January 2000 – Nova Scotia: From April 2001 – Prince Edward Island: From April 2004
Trending Issues	<ul style="list-style-type: none"> – British Columbia: From January 2006 – Yukon: From January 2007 – Newfoundland and Labrador: From April 2008 – Ontario: From April 2010
Comments	<ul style="list-style-type: none"> – First Nations and Inuit Health Branch: From October 2010 <p>Not applicable</p>